Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04822363 · ClinicalTrials.gov registry record · Early Phase 1
The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry
A Early Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 112
- Enrollment target
NCT04822363 is a Early Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 112 participants.
The verdict
NCT04822363, a Early Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
The purpose of this study is to test a novel diagnostic immunoassay of platelet function and compare it to the current gold standard platelet function assay by testing the response to aspirin and clopidogrel in a group of healthy volunteers and severely obese individuals and comparing the accuracy of the two tests. The secondary goals will be to evaluate the pharmacodynamic parameters of the antiplatelet agents across the two testing modalities and refine the cutoffs used for the novel assay.
Interventions
- DRUG Aspirin
- DRUG Clopidogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2021-08-20 |
| Est. Completion | 2025-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04822363
The ClinicalTrials.gov registry entry for NCT04822363 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aspirin is the first listed.
NCT04822363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04822363 about?
NCT04822363 is a clinical study titled "The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry". The purpose of this study is to test a novel diagnostic immunoassay of platelet function and compare it to the current gold standard platelet function assay by testing the response to aspirin and clopidogrel in a group of healthy volunteers and severely obese individuals and comparing the accuracy o...
What is the current status of trial NCT04822363?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 112 participants. The study started on 2021-08-20. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT04822363?
The interventions under investigation include: Aspirin (DRUG), Clopidogrel (DRUG).
Who is sponsoring clinical trial NCT04822363?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.